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Abstract
BACKGROUND: Colorectal cancer is one of the most common and deadly cancers, particularly
in persons greater than 50 years of age. Most colorectal malignancies are slow-growing, making
regular screening increasingly important to decrease morbidity, mortality, and cost of treatment.
Cologuard® serves as an effective and non-invasive colorectal cancer screening modality for
average-risk adults.
PURPOSE: The purpose of this study was to evaluate the impact of a provider-based educational
intervention on the knowledge, attitudes, self-efficacy, and ordering rates of Cologuard® among
primary care providers.
METHODS: This study was a single-center, pre/post implementation study of the effectiveness
of a provider-based educational intervention using a validated resource tool from the American
Cancer Society. The first stage of the project featured a pre/post-test examination of the
knowledge, attitudes, and self-efficacy related to Cologuard® of 14 primary care providers
before and after an educational intervention for providers in November 2018. The second stage
of the project included a separate pre/post-test design to determine the effect of the educational
intervention on provider order rates of Cologuard® using 200 randomly selected charts prior to
the intervention during the months of August through October 2018, and 200 randomly selected
charts after the intervention during the months of December 2018 through February 2019 for
patients meeting screening qualifications.
RESULTS: Of the 18 providers who attended the educational program, 14 completed and
returned pre- and post- tests. There was a statistically significant increase in provider knowledge
(p<0.001) and self-efficacy (p=0.002) from the pre- to post- intervention periods. There was no
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statistically significant difference in attitudes (p=0.142) or Cologuard® order rates (p=0.660)
from the pre- to post- intervention periods.
CONCLUSION: Provider-based educational programs serve as an effective intervention to
address certain measures in practice. Increases in provider knowledge and self-efficacy related
to Cologuard® were seen in the post-intervention period, and while there was not a statistically
significant difference in provider attitudes, it is important to note an increase on the measurement
scale did occur. Future implications for practice may involve alternate solutions to improving
Cologuard® order rates, though this initiative may provide necessary first-steps to facilitate
organizational changes that would lead to an increase in Cologuard® orders.
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The Effect of a Provider-Based Educational Program on Knowledge, Attitudes, Self-Efficacy,
and Order Rates of Cologuard® in a Primary Care Clinic
Introduction
In the United States, colorectal cancer (CRC) is the third most prevalent cancer and
second deadliest cancer, with 139,992 new cases diagnosed and 51,651 deaths occurring in 2014
(Centers for Disease Control and Prevention [CDC], 2017b). Most colorectal malignancies are
slow-growing, making regular screening important in decreasing morbidity and mortality.
According to the American Cancer Society (ACS), preventive screening and early detection of
pre-cancerous or cancerous growths greatly improve survival rates and decrease costs associated
with long-term treatment (2014). The U.S. Preventive Services Task Force (USPSTF) has issued
a Grade A recommendation for CRC screening to begin at age 50 for average-risk adults,
continue until age 75, and incorporate methods such as fecal occult blood testing,
sigmoidoscopy, or colonoscopy (2015).
Although CRC screening rates are on the rise, an opportunity exists for providers to
better screen patients and discuss available screening options, thereby increasing screening
uptake rates and improving overall outcomes. Providers play a pivotal role in decreasing CRC
by recommending screening to eligible patients. Provider recommendations are one of the main
determinants in predicting the utilization of preventive services (Atassi, 2012).
While colonoscopy remains the gold standard among CRC screening modalities, patients
may have an aversion to this procedure or would prefer less invasive options. Cologuard®, the
only single-test screening modality available in the U.S. to combine a multi-target stool DNA
test with fecal immunochemical testing (FIT), serves as an effective method to detect adenomas
and CRC for patients preferring alternative screening options (ACS, 2017a). The purpose of this
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project was to determine the effectiveness of a provider-based educational intervention on the
knowledge, beliefs, self-efficacy, and ordering rates of Cologuard® in a primary care clinic.
Background
In 2015, approximately 774,000 deaths worldwide resulted from CRC (World Health
Organization [WHO], 2018). Of those who develop colorectal malignancies, 90% are in persons
50 years and older (ACS, 2014). In the U.S., morbidity and mortality due to CRC far exceeds
most other cancers (CDC, 2017b). Kentucky’s CRC incidence rates rank among the highest in
the nation, with an incidence rate of 49.4 per 100,000 persons and fatality rate of 17 per 100,000
persons in 2014 (CDC, 2017a).
Screening Recommendations
CRC screening is defined by the American College of Gastroenterology (ACG) as the
process by which early-stage cancers and pre-cancerous growths are detected in asymptomatic
persons without previous history of malignancy or pre-cancerous cells (Rex et al., 2017). The
CDC (2019) and USPSTF (2015) recommend the screening process begin at age 50 through age
75 for all persons with average-risk of developing CRC using colonoscopy, flexible
sigmoidoscopy, or stool-based tests. These two organizations suggest providers use special
clinical consideration for CRC screening in African Americans, but maintain age 50 as an
appropriate age to begin screening (Williams, 2016). With evidence to suggest that CRC
incidence and mortality is greater in African Americans, the ACG recommends screening in this
patient population to begin at age 45 (Rex et al., 2017). In 2018, the ACS updated their
recommendations for average-risk adults of any racial or ethnic group to begin screening at age
45 and end at age 75 or a projected life expectancy of more than ten years beyond age 75 (ACS,
2018).
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When discussing CRC screening with patients, it is important for the provider to be
aware of evidence-based clinical recommendations. Exceptions for ‘average-risk’ persons
include the following:
a) Symptomatic (experiencing signs or symptoms of potential colorectal disease,
including but not limited to: lower abdominal pain, bloody stools, positive guaiac or
FIT test)
b) Personal history of CRC or adenomatous polyps
c) Family history of CRC (first-degree relative with CRC or advanced adenoma
diagnosed <60 years of age OR two first-degree relatives with CRC or advanced
adenoma)
d) Personal history of inflammatory bowel disease (such as Crohn’s disease or ulcerative
colitis)
e) Hereditary colorectal cancer syndrome (such as familial adenomatous polyposis
[FAP] or Lynch syndrome)
f) Personal history of radiation to the abdomen or pelvis
g) Personal history of surgical CRC resection
(Centers for Medicare and Medicaid Services [CMS], 2014; Rex et al., 2017; USPSTF,
2015).
Persons at greater-risk for developing CRC should consult with their healthcare provider
about screening recommendations, including age to begin screening, appropriate screening
strategy, and follow-up intervals.
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Screening Modalities
Joint guidelines separate CRC screening options into cancer prevention tests and cancer
detection tests. Colorectal cancer prevention tests are preferred and should be offered first, due
to the ability to directly visualize the colon and capture imaging of malignancies or polyps.
While CRC detection tests have lower sensitivity for polyps and malignancies compared to
imaging tests, these options are validated for their use in practice and should be offered to
patients who decline colonoscopy or other CRC prevention tests (Rex et al., 2017). A positive
(or abnormal) screening result from any CRC detection test requires a follow-up colonoscopy to
further investigate. It is important to note that older guaiac-based fecal occult blood testing
should not be used for screening. CRC screening recommendations of the most commonly used
modalities are summarized in Table 1.
Cologuard®
Although CRC prevention tests—such as colonoscopy or flexible sigmoidoscopy—are
the preferred screening modality, early detection tests are widely used and play an important role
in CRC screening (Rex et al., 2017). Many patients have an aversion to invasive exams, or have
issues with accessibility or availability in regards to medical procedures. Evidence from the
ACS suggests a large proportion of patients, when given the choice of invasive exam versus
stool-based tests, prefer the less invasive option (2017a). Additionally, modeling studies propose
that outcomes of high-quality stool-based screening tests are nearly comparable to colonoscopies
when strict adherence to screening intervals and appropriate follow-up occur (ACS, 2017a).
Deoxyribonucleic acid (DNA) biomarkers are shed into the stool as colorectal cancers
grow and adenomas degenerate. Cologuard®, the only single-test screening modality available
in the U.S. to combine FIT with a multi-target stool DNA test, serves as an effective method to
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detect even trace amounts of these molecular markers for CRC and pre-cancerous neoplasias
(ACS, 2017a). Because Cologuard® is a fairly new test, with Food and Drug Administration
(FDA) approval just within the past five years, technology and data about this modality are still
evolving. However, data across numerous organizations and studies reveals a pattern of much
higher sensitivity compared to all other stool-based tests (Song & Li, 2016; ACS, 2017a).
One systematic review of several large randomized-controlled trials reveals Cologuard®
as 92.3% sensitive in detecting CRC, whereas FIT testing alone averaged a sensitivity of 73.8%
(Song & Li, 2016). These numbers vary only slightly when compared to figures from studies
published by the ACS. Cologuard® proved to be much less specific, however, than its FIT
screening counterpart. The same literature review conducted by Song and Li (2016) revealed
specificity of 86.6% for Cologuard®, and specificity of 94.9% for FIT testing; these percentages
are akin to those distributed by the ACS. A positive test result warrants follow-up with a
colonoscopy. Repeat screening with Cologuard® is recommended every three years for patients
with a negative screening result.
Cologuard® is a favorable test for patients preferring alternative screening options, as it
is safe, commonly used in primary practice, and is covered by most insurers, including Medicare
and Medicaid in the state of Kentucky (CMS, 2014). Unlike many other stool-based tests, results
from Cologuard® are not affected by medication or food, and require only a single bowel
movement to complete screening (ACS, 2017a). For patients who choose Cologuard®, the
screening kit is mailed directly to the patient’s home, contains directions in English and Spanish
with the kit, and includes a pre-addressed, pre-paid box for shipping the sample directly to the
Direct Sciences lab once a patient collects it. Patients facing lack of access to care, limited
availability for bowel prep or travel, or who prefer less invasive modalities can benefit from
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Cologuard®. One main takeaway for providers is any screening is better than no screening, and
providing the patient with screening options does improve screening uptake rates (ACS, 2017a).
Provider Education to Impact Screening
Provider-based interventions are one strategy that can be used to influence CRC
screening rates. A randomized controlled trial (RCT) by Lane, Messina, Cavanaugh, and Chen
(2008) focused on provider education as an intervention to improve CRC screening and patient
adherence to screening recommendations. The intervention included a PowerPoint presentation
of materials, interactive questionnaires, discussion of behavioral approaches, and distribution of
educational resources to providers in the experimental group. The control group did not receive
the educational intervention. The results of that study revealed a statistically significant increase
in patient self-reports of providers recommending CRC screening in the intervention cohort
compared to the control group (p=0.04). Additionally, short and long term improvement in
completion of CRC screening occurred among patients seen by providers in the experimental
group, including a 16% increase from baseline screening rates after 1 year (p<0.001) (Lane,
Messina, Cavanaugh, & Chen, 2008).
Another RCT in Appalachian Kentucky used academic detailing—an educational
outreach method whereby trained healthcare professionals travel to practice sites to deliver
evidence-based information to other healthcare workers—as the provider-based intervention
(Dignan et al., 2014). At the cessation of the study, colonoscopy orders increased for
intervention sites that recommended CRC screening (p<0.01) (Dignan et al., 2014).
One study by Sheinfeld-Gorin et al. (2000) used a pre- and post- test design to determine
provider knowledge and identify potential screening barriers in an underserved urban
community. The investigators of this study selected a provider-based educational session, again
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using academic detailing, as the intervention. The findings included a statistically significant
difference in provider knowledge scores before and after the educational intervention (p<0.001)
over an 18-month period. Providers in the intervention group also reported significantly fewer
barriers to screening practices in the post-test period than providers in the control group (p<0.05)
(Sheinfeld-Gorin et al., 2000).
A descriptive study by Rim et al. (2009) used surveys to examine the relationship
between knowledge, attitudes, beliefs, and CRC screening practices of 109 healthcare
professionals, including nurses and providers. The results revealed a strong association between
provider knowledge and higher CRC screening rates (p=0.02), but no statistically significant
correlation between attitudes, beliefs, and CRC screening practices (Rim et al., 2009).
Additionally, the CRC screening practices of individual providers had no statistically significant
correlation to increased rates of patients screened.
Addressing Barriers to Screening
Screening for CRC has the potential to detect cancerous and pre-cancerous lesions at
early stages, thereby improving long term survival rates. Despite clinical recommendations,
about one-third of adults ages 50-75 have not been screened for CRC (ACS, 2017a). A recent
study by the CDC revealed that underwhelming CRC screening rates may be attributed to patient
evasion of tests because of bowel preparation, unfamiliarity about screening options, fear of
invasiveness from colonoscopy, fear of complications, negative familial history, lack of
symptoms, unawareness by the provider to screen, and absence of recommendation in general by
the provider (Cooper & Gelb, 2016). Additionally, disparities among minority populations,
uninsured persons, and persons of lower income levels exist when evaluating CRC screening and
follow-up screening (ACS, 2017a). A literature review conducted by the ACG revealed one of
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the biggest disparities exists among African American populations, as socioeconomic and
genetic factors likely influence lower CRC screening rates and higher instances of morbidity and
mortality (Rex et al., 2017). Men and women of all ethnicities and races can develop CRC, with
slightly higher incidences in male populations; the risk of developing CRC increases after age 50
for both genders (CDC, 2017b).
Using a multiple-option approach, whereby the provider offers and discusses two or more
screening tests to the patient, is a recommended strategy that the ACG suggests in order to
encourage informed decision-making and increase CRC screening follow-through (Rex et al.,
2017). Patients are more likely to embrace preventive health if the services are recommended by
a healthcare provider (Atassi, 2012).
Theoretical Framework
In 1975, Icek Ajzen and Martin Fishbein began reviewing studies in an attempt to prove
that intention, rather than attitude toward a particular behavior, was the driving cause behind the
behavior. With this assumption, the Theory of Reasoned Action (TRA) was formed in
1980. Ajzen and Fishbein’s TRA framework ascertained that behavior is voluntary and carried
out upon intent at a certain time. Intention, by definition, is a willing and purposeful drive
behind a behavior and aids in predicting whether or not a person will participate in the given
behavior (Ajzen & Fishbein, 1980). The TRA model pertained only to voluntary actions
(volitional control). Instances that lacked volitional or purposeful control threatened the validity
of the TRA model, so the Theory of Reasoned Action was revised into the Theory of Planned
Behavior (TPB), which is simply the TRA model plus the perceived behavioral control factor.
Ajzen and Fishbein determined that intention to perform a behavior is determined by the
following four paradigms: (a) attitude, which encompasses a person’s positive or negative
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assessment of an action, (b) subjective norms, or the perceived expectation a person believes
others have of a given behavior, (c) volitional control, which is simply the conscious decision to
do or not do an action, and fourth, (d) behavioral control, defined as one’s perception of how
easy or difficult a task will be.
Attitudes
The first of these factors is attitudes, which describe the value one places on a certain
behavior and affect the odds of a person to perform that behavior (Ajzen & Fishbein, 1980). For
example, if a provider views CRC screening as beneficial, his or her attitude will be favorable
and the likelihood of screening for CRC will be greater. Adversely, if a provider views a
behavior as negative, harmful, inconvenient, or not valuable, then it is less likely for that person
to suggest the given behavior.
One strategy that can be used to assess provider attitudes is a questionnaire using openended responses or a measurement tool, such as the Likert scale. If the questionnaire reveals
positive provider attitudes, corroboration and assurance from other healthcare personnel can
reinforce those beliefs. After identifying providers who do not have a positive attitude toward
CRC screening, it may be helpful to reiterate the risks of CRC, as well as benefits of regular
screening with support from facts obtained from the CDC, USPSTF, and other organizations.
Following the premise of the TRA/TPB model, a positive change in attitude will lead to
increased screening behaviors by providers, which could ultimately impact screening uptake
rates by patients.
Subjective Norms
The second factor influencing intention is subjective norms, which answers the question,
“How do I think others feel about this behavior?” This construct of the TRA/TPB model
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deals with the perceived notions of others, rather than explicit expectations (Ajzen & Fishbein,
1980). The understanding an individual has about whether referent groups will approve or
disapprove of an action influences the probability of that individual to participate in a given
behavior. Examples of ‘referent individuals’ include friends, coworkers, role models, or anyone
else who an individual aims to please. Healthcare providers are among the most influential of
the referent groups (Atassi, 2012).
Using this construct of the TRA/TPB model, it can be inferred that a provider who
believes people within the medical community place importance on CRC screening, has
coworkers who utilize screening, or believes that society supports screening and surveillance,
would have the intention of pleasing these groups of individuals by following screening
recommendations. On the contrary, if one did not feel that referent groups believed in and
standardized the practice of CRC screening, he or she would be less likely to screen patients.
Offering verbal support of screening, adhering to guidelines and specific practice sites’
recommendations for screening, and being a champion for CRC screening within the medical
community are ways providers can act as referent individuals to other healthcare workers.
Volitional Control
Volitional control purports that one can freely and deliberately exercise the power to act
upon a decision (Ajzen & Fishbein, 1980). It is the third factor of the TRA/TPB model to
influence intention. Despite strong recommendations from evidence-based guidelines, the
conscious decision to discuss, order, and refer screening is ultimately left up to the provider.
Similarly, patients have the right to refuse medical services, thus exercising volitional control on
the situation.
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Behavioral Control
Not all situations and environments allow for volition, especially when more than one
outside factor or determinant is present. Behavioral control, which is an assumption of ease
versus difficulty of a behavior, is more useful in determining behaviors in low-volition
circumstances (Gochman, 1997). This construct deals with the perceived control over an action,
rather than the actual ability of carrying out the action.
For example, a provider with strong perceived control of screening may believe he or she
has time to discuss screening, has resources readily available, or has an appropriate level of
knowledge and understanding about CRC screening. Based on the TRA/TBP theory, a provider
who feels that CRC screening is without major challenges will have greater intent to carry out
screening. A healthcare professional with weak perceived control, however, might view CRC
screening as an action that is unmanageable. This provider might feel that screening is too
cumbersome or cannot be achieved during a specific time period. Assessing providers’
perceptions of screening barriers is one way to determine behavioral control and subsequently
formulate solutions.
Purpose
The purpose of this project was to determine if a provider-based educational intervention
would increase primary care providers’ (a) knowledge of current Cologuard® recommendations
and procedures for use; (b) attitudes about Cologuard®; (c) self-efficacy of prescribing
Cologuard®; and (d) ordering rates of Cologuard®. This project was part of a larger quality
improvement (QI) initiative in a large primary care clinic.
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Methods
Design
This study was a single-center, pre/post implementation study of the effectiveness of a
provider-based educational intervention using a validated resource tool from the ACS. The first
stage of the project featured a pre/post-test examination of the knowledge, attitudes, and selfefficacy related to Cologuard® of 14 primary care providers before and after an educational
intervention for providers in November 2018. The second stage of the project included a
separate pre/post-test design to determine the effect of the educational intervention on provider
order rates of Cologuard® using 200 randomly selected charts prior to the intervention during
the months of August through October 2018, and 200 randomly selected charts after the
intervention during the months of December 2018 through February 2019 for patients meeting
screening qualifications.
Setting
This project took place at a primary care clinic in central Kentucky. This institution
primarily serves residents of central Kentucky seeking an array of comprehensive services,
including preventive medicine, screening, wellness exams, care for chronic conditions, and acute
medical visits.
Quality Improvement
Several solutions exist to address the problem of subpar CRC screening rates, including
patient-based interventions and processes aimed at provider or community health center practice
improvement. QI teams may provide valuable information to a clinic by conducting
performance reviews, identifying weaknesses in practice, and creating/monitoring improvement
processes (Agency for Healthcare Research and Quality [AHRQ], 2013).
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The preventative health QI team in the clinic included several interdisciplinary members
from the areas of nursing, medicine, administration, and ancillary staff. The goal of the QI team
was to identify a problem within the clinic (underutilization of Cologuard®) and formulate
processes (Plan-Do-Study-Act cycles) to change the problem (increase acceptance and order
rates of Cologuard®). Monthly team meetings were held to discuss progress and make
adjustments to the improvement cycles as necessary. The timeline for meetings began in
February 2018 through September 2018, with a presentation of team efforts occurring at a clinic
meeting in November 2018.
Plan-Do-Study-Act Cycles
Plan-Do-Study-Act (PDSA) cycles are a common approach of QI teams to produce
practice improvement that is driven by a change (AHRQ, 2013). PDSA cycles aim to answer
three main questions: “What are we trying to accomplish? How will we know that a change is an
improvement? What change can we make that will result in improvement?” (Institute for
Healthcare Improvement [IHI], 2019). The IHI (2019) outlines four cyclical steps of the PDSA
approach. The first step in the PDSA cycle is Plan, which includes strategizing how tests or
observations can be used to collect data, stating an objective, predicting intended and unintended
consequences, and developing a blueprint to test the change. This portion of the PDSA cycle
should answer “who, what, where, when, and how.” The second step is Do, which involves
trialing the test on a small scale, recording outcomes and observations, and beginning to analyze
data. Study is the third step, when members are tasked with completing data analysis, comparing
actual outcomes to the predicted outcomes, summarizing data, and reflecting on what they
learned. Finally, the Act stage involves taking what was learned from the test and making
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necessary edits to the change. Figure 1 illustrates the four phases as a sequential process that can
be repeated to produce multiple cycles in order to drive change.
Figure 1: PDSA Steps

(IHI, 2019).
For the Plan phase, the QI team identified CRC screening as the subject of process
improvement, hypothesized ways to increase screening rates, and proposed an intervention
aimed at addressing underutilization of Cologuard® in the clinic. The Do phase of the PDSA
cycles was an in-person provider education session during the clinic’s Combined Team meeting
in November 2018, co-led by the primary investigator (PI) of this project and a resident from the
QI team. Data analysis occurred during the Study phase. This project report does not include
the Act phase.
Educational Intervention
The “Clinician’s Reference: Stool-Based Tests for Colorectal Cancer Screening,” (ACS,
2017a) was selected as a part of the provider-based educational intervention. The toolkit—
which combines recommendations from the ACS, CDC, and USPSTF—was an optimal solution
because it is geared toward primary care providers and summarizes the endorsements from
2
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several health organizations in a concise, straightforward, and easily presented format. The
reference tool features evidence-based facts, recommendations for practice, and comparisons
among various stool tests. It focuses on empowering the provider to have a dialogue with
patients who favor stool-based screening options.
The first part of the project involved a pre/post-test design to examine primary care
providers’ knowledge, attitudes, and self-efficacy related to Cologuard®, with the independent
variable between the pre/post-survey being a provider-based education session. A copresentation with the QI team’s lead resident incorporated an overview of PDSA cycles and the
clinic’s current procedures for ordering Cologuard®. Currently, the clinic’s procedure for
providers ordering Cologuard® includes: provider and patient agree upon Cologuard® as
screening modality; clinic staff (provider, nurse, or certified surgical technologist [CST]) fills out
the order sheet; staff faxes order sheet directly to Direct Sciences laboratory; Cologuard® sends
test kit directly to patient; patient mails sample to lab within 24 hours of collection (if no sample
is received within 60 days of order date, provider is notified by fax); provider receives test
results via fax approximately two weeks after sample is received. This information was
reviewed using a PowerPoint presentation created by the lead resident. The Clinician’s
Reference was then projected onto a screen, and the PI reviewed its content aloud to those in
attendance at the meeting.
Sample
Providers
Inclusion criteria for this sample included primary care providers (attending physicians,
resident physicians, and advanced practice providers [APP]) who attended the clinic’s Combined
Team meeting on November 16, 2018. Exclusion criteria included involvement in the clinic’s
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CRC QI team or providers who did not attend the meeting. Of the 18 primary care providers at
the meeting, only 14 completed a pre/post-test. The identity of those 14 providers is anonymous.
Medical Records
A total of 200 medical records were randomly selected from patients who were seen in
clinic prior to the intervention between August 1, 2018 and October 31, 2018. Another 200
medical records were randomly selected from patients who were seen in clinic after the
intervention between December 1, 2018 and February 28, 2019. Inclusion criteria were: persons
50 through 75 years of age; attending the primary care clinic only; seen as a Health Maintenance,
Established Patient, or New Patient visit; seen by a primary care provider who attended
November’s Combined Team Meeting. Exclusion criteria included: not average-risk as defined
by USPSTF; <50 years, >75 years; identified as a duplicate patient; or provider not in attendance
at interventional November meeting.
Institutional Review Board Approval
An interprofessional training grant was approved by the affiliated university’s
Institutional Review Board (IRB). After IRB approval, the QI team was able to begin PDSA
cycles and an individual project stemming from QI group work began.
Measures
A survey of knowledge, attitudes, and self-efficacy of Cologuard® was created by the PI
and based on the ACS’s Clinician’s Reference and verbal presentation from the PI and QI leadresident (see Appendices A and B). The survey was distributed to the providers for completion
at the November meeting. The survey was the same for both the pre- and post- intervention
period, and included five knowledge-based questions, five questions about attitudes, and five
questions about self-efficacy. Additionally, the post-test included an optional line for comments.
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The findings of the pre- and post- tests were scored based on correct answers for the knowledgebased questions (potential range 0-5, highest score = 5), and measured using a Likert scale for
questions regarding attitudes (potential range 5-25, highest score = 25) and self-efficacy
(potential range 5-25, highest score = 25).
Order rates of Cologuard® were collected from 200 randomly-selected charts of patients
seen in clinic prior to November’s intervention (August 1, 2018 – October 31, 2018), and 200
randomly-selected charts of patients seen after the intervention (December 1, 2018 – February
28, 2019) using sample inclusion and exclusion criteria. The results were stored in a Microsoft
Excel spreadsheet. See Table 2 for summary of variables.
Data Collection
All study data were kept confidential and stored on the PI’s personal password-protected
computer with a secure server. Patient identifiers were not included in data sets. The first stage
of data collection included distribution of pre- and post- tests to all 18 providers in attendance at
the November meeting. The identity of the participating providers was anonymous. The 14
completed surveys were recollected, and paired pre- and post- test responses were then entered
into Microsoft Excel by the PI.
The second stage of data collection involved chart reviews of patients who met inclusion
criteria for the study. An electronic list was provided by a clinic staff member of all patients
who met inclusion criteria for the months of August through October 2018. An online random
number generator was used to provide 200 random numbers, which correlated to 200 persons on
the numbered list of patients meeting inclusion criteria for the pre-intervention period. Of those
200 charts that were audited, 12 were excluded for the following reasons: provider participated
on QI team; seen as a nurse visit or in department other than the primary care clinic; past medical

19
2

EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®
history of Crohn’s disease; duplicate patient encounter. The random number generator was again
used to provide 12 additional numbers in order to attain a total chart count of 200 patients. The
following data for the pre-intervention period were entered into Microsoft Excel: correlating
chart number; date of service; visit type; provider type; meets screening criteria (Y/N); CRC
screening up to date (Y/N); colonoscopy ordered/scheduled (Y/N); Cologuard discussed (Y/N);
Cologuard ordered (Y/N); Notes.
A similar process was repeated for the post-intervention chart review. An online number
generator was again used to generate 200 random numbers that correlated with a numbered list
of patients meeting inclusion criteria from December 2018 through February 2019. There were
23 charts excluded for the following reasons: provider participated on QI team; provider not in
attendance at interventional meeting; patient less than 50 years of age; patient greater than 75
years of age. The online random number generator was used to produce 23 additional numbers.
200 charts for the post-intervention period were reviewed, and data were entered into Microsoft
Excel using the same organizational headings from the pre-intervention period.
Data Analysis
Statistical analysis was completed using IBM SPSS statistical software version 24.
Descriptive analysis was used to determine frequencies with percentages to describe nominal
demographic variables. Differences between variables in the samples before and after the
intervention were assessed using paired sample t-tests to assess changes in attitudes and selfefficacy, and McNemar’s test for items on knowledge pre/post intervention. Variances in the
proportion of Cologuard® ordering rates before and after the intervention were assessed using
chi-square analyses.
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Results
Demographics
Of the 18 primary care providers in attendance at the meeting, 14 completed pre- and
post- tests. The ratio of male to female providers was even. Half of the providers in attendance
were resident physicians. Most of the providers reported less than five years of experience. See
Table 3 for provider demographics.
Provider Knowledge
Overall, provider knowledge increased after the educational intervention (see Figure 2).
The average provider score prior to the education was 3.36 correct responses out of 5 items
(SD=1.15). After the intervention, the average provider knowledge score was 4.71 correct
responses out of 5 items (SD=0.61). McNemar’s test showed a statistically significant difference
in knowledge scores before and after the intervention (p<0.001) (see Table 4).
Provider Attitudes
The overall means score of provider attitudes increased from 19.41 out of a possible 25
points (SD=3.11) before the intervention to 20.64 out of a possible 25 points (SD=1.74) after the
intervention. Though there was an increase in positive attitudes relating to Cologuard®,
statistical analyses revealed that a change in provider attitudes pre- and post- intervention was
not statistically significant (p=0.142) (see Table 4 and Figure 3).
Provider Self-Efficacy
Provider self-efficacy related to Cologuard® increased after the educational intervention.
The overall mean for provider self-efficacy increased from 19.07 out of a possible 25 points in
the pre-intervention period (SD=4.67) to a mean of 23.29 out of a possible 25 points in the post-
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intervention period (SD=1.98). Thus, the change in self-efficacy from the pre- to post- test was
statistically significant (p=0.002) (see Table 4 and Figure 4).
Order Rates of Cologuard®
Pre-Intervention
The PI performed a chart review of 200 randomly selected patients who met all inclusion
criteria and for whom screening was indicated during the pre-intervention months of August
through October 2018. Of those 200 patients, 151 (75.5%) had documentation in at least one
place in the Electronic Health Record (EHR) of up-to-date CRC screening. The remaining 49 of
200 patients (24.5%) did not have documentation in the EHR to indicate CRC screening was
current.
Of the 49 patients who were not up-to-date on screening, 31 (63.3%) did not have CRC
screening ordered during the patient-provider encounter. Reasons for not ordering some
modality of CRC screening included: patient refused, provider will discuss at subsequent visit, or
no reason documented in EHR. Of the 49 patients without previously documented CRC
screening, 18 (36.7%) had CRC screening ordered at the time of their clinic visit.
Of the 18 patients who had CRC screening orders placed during the pre-intervention
period, 17 (94.4%) had colonoscopy orders placed, and Cologuard® was ordered for one patient
(5.6%). See Figure 5 for comparison of order rates pre- and post- intervention.
Post-Intervention
The PI performed a chart review from 200 randomly selected patients who met all
inclusion criteria and for whom screening was indicated during the post-intervention months of
December 2018 through February 2019. Of those 200 patients, 142 (71%) had documentation in
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at least one place in the EHR of up-to-date CRC screening. The remaining 58 of 200 patients
(29%) did not have documentation in the EHR to indicate CRC screening was current.
Of the 58 patients who were not up-to-date on screening, 26 (44.8%) did not have CRC
screening ordered during the patient-provider encounter. Reasons for not ordering some
modality of CRC screening included: patient refused, provider will discuss at subsequent visit, or
no reason documented in EHR. Of the 58 patients without previously documented CRC
screening, 32 (55.2 %) had CRC screening ordered at the time of their clinic visit.
Of the 32 patients who had CRC screening orders placed during the post-intervention
period, 27 (84.3%) had colonoscopy orders placed, 3 (9.4%) had fecal occult blood test (FOBT)
ordered, and 2 (6.3%) had Cologuard® ordered. See Figure 5 for comparison of order rates preand post- intervention.
Finally, a chi-square test was used to analyze Cologuard® order rates for patients who
were not up-to-date on CRC screening in the pre- and post- intervention periods. Analyses
revealed 𝑥 2 =0.193 and no statistically significant difference in Cologuard® order rates (p=0.660)
from the pre- to post- intervention periods (see Table 5).
Barriers Identified
At the end of the post-test, providers were asked to leave additional comments explaining
their answer. In doing so, the PI hoped to gain insight to potential barriers of Cologuard® use in
practice and identify potential solutions moving forward. Eight out of 14 providers left
comments.
Five providers commented there is no specific place to document Cologuard® within the
EHR. Furthermore, many of these providers added there is no consistent place populated within
the EHR to see if screening was completed or what the results were. Solutions to these barriers
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included provider comments such as “create EHR result field for Cologuard” ; “in patient
flowsheet where we document mammogram, eye exam, etc. make a column for Cologuard so it
can easily be seen whether they have had it and when” ; “make a consistent location under same
heading as colonoscopy.”
The following remarks represent perceived barriers of Cologuard® from providers in this
clinic: “the form is a natural barrier like any paperwork in clinic” ; “time to complete order form
– improving with my new CST as she is more involved” ; “a handout would help for patients
literate enough, like main points on a card.”
Discussion
Influencing Knowledge, Attitudes, Self-Efficacy, and Order Rates
The use of a QI team is an effective way to identify problems within a setting, gain
perspective from different disciplines, hypothesize potential solutions, and plan and execute
practice improvement cycles with the aim of achieving a goal set by the QI group. In both
collaborative and individual efforts, the QI group and PI at a large primary care clinic sought to
improve variables related to Cologuard®, including provider knowledge, attitudes, self-efficacy,
and order rates of Cologuard®.
A provider-based educational intervention improved provider knowledge and selfefficacy related to Cologuard® use in clinic. The intervention did not, however, change attitudes
toward Cologuard® during the time period identified for this study. Though the overall mean for
attitudes increased, the change was not statistically significant. Provider order rates of
Cologuard® did not increase after the educational intervention.
The outcomes of this experiment are similar to other studies in the literature. SheinfeldGorin et al. (2000) used a similar pre- and post- test design with an educational intervention.
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The study concluded that there was a statistically significant difference in provider knowledge
scores before and after the educational intervention (p<0.001). Additionally, barriers were
identified and included in the discussion of the study (Sheinfeld-Gorin et al., 2000).
The study by Rim et al. (2009) revealed a strong association between provider knowledge
and higher CRC screening rates (p=0.02), but no statistically significant correlation between
attitudes, beliefs, and CRC screening practices. The results of the PI’s study do not take into
account overall screening rates in the pre- to post- intervention period. It would be interesting,
however, to examine whether the findings of Rim et al. could be generalized by looking at
overall screening (beyond just Cologuard®) in the PI’s primary care clinic.
Application of Theory
This study supports the use of the TRA/TPB framework. One of the measures examined
in the pre- and post- surveys was provider attitudes. Based on this theoretical framework, if an
increase in attitudes will increase the likelihood of a behavior, then one can assume an increase
in provider attitudes will lead to increased CRC screening by providers. It is important to note
there was an increase in positive attitudes relating to Cologuard®, although it was not
statistically significant (see Figure 3). The second concept of the TRA/TPB framework is
subjective norms. This aspect is applicable because referent groups often share a commonality;
the shared sample demographic was profession (primary care providers). In accordance to the
TRA/TPB theory, a provider will be more likely to screen for CRC if he or she feels that his or
her referent groups also support, utilize, and value CRC screening. Self-efficacy ties closely
with behavioral control—or assumed ease versus difficulty of a behavior. This study revealed a
statistically significant change in provider self-efficacy related to Cologuard® in the pre- and
post- intervention periods.
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Implications for Practice
Providers who offered written feedback after the intervention and post-test allowed for
identification of barriers and possible solutions. One way to integrate results of this study into
practice is to consider adding a clear, logical, and pre-populated field within the EHR to address
Cologuard® orders and results. This step may alleviate or eliminate the provider from having to
involve the nurse or CST in completing the paper order form, waiting for a fax or notification not
otherwise tasked to the provider, or searching through the EHR to find if and when Cologuard®
was completed.
Another implication for future practice includes the use of a provider portal as a means to
potentially increase order rates and overall satisfaction with the ordering and result retrieval
processes. Through the Cologuard® website, institutions can create an online portal for placing
orders and reviewing results. Utilizing the provider portal could potentially address the issue of
paper forms identified as a barrier by providers in this study. Orders placed electronically will
be automatically uploaded onto the portal, and faxed order requests—this clinic’s current
procedure for ordering Cologuard®—will deliver results via both fax and online portal
(Cologuard, 2018). Confirmation of orders and results are stored within the portal and can be
easily accessed for a particular patient, reducing the need for providers to search the EHR or
faxed results for this information.
Patient-based interventions could also address underutilization of Cologuard® for
patients preferring non-invasive CRC screening. Examples of interventions that educate and
empower the patient, rather than the provider, include: written materials (i.e. pamphlets, posters,
or patient handouts), and providing the patient with access to health information on the internet
(i.e. Cologuard® website or other evidence-based sites).
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It is worthwhile to note the potential impact of provider-based interventions on certain
measures. Because a statistically significant change was seen in provider knowledge and selfefficacy of Cologuard® in the post-intervention period, it may be beneficial to conduct
educational sessions on other topics, such as various MACRA measures or weaker areas of
practice, to boost knowledge, self-efficacy, and possibly provider attitudes towards those
matters.
Implications for Further Study
The need to determine the reliability and validity of the provider survey is one important
implication for further study, as the true reliability and validity remains unknown; if this cannot
be achieved, consideration of a different validated survey may be warranted. It may also be
useful to extend the time frame of the study to determine whether knowledge, attitudes, and selfefficacy were sustained over time. Finally, a multi-site design would be ideal to test replicability
and generalizability of the study.
Limitations
Limitations of this study include a small sample size of providers (n=14) from which
demographics, knowledge, attitudes, and self-efficacy were examined. A larger sample size
would have been more ideal in order to measure more accurate variances in measures pre- and
post- intervention. This was a single-center design over the course of a few months. Increasing
the project to a multi-center study for a longer amount of time may help to generalize and
compare outcomes. The reliability and validity of the pre- and post- test has not been
determined, as it was generated by the PI and not trialed prior to this study. Additionally, data
collected from the pre- and post- tests involve answers which may reflect responder bias.
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Additional limitations include small sample sizes in both the pre- and post- intervention
chart review phases. Although 200 charts were reviewed in both the pre- and post- periods, 151
out of 200 patients were up-to-date on screening recommendations in the pre-intervention phase.
This left only 49 out of 200 patients needing CRC screening. Similarly in the chart review for
patients seen after the intervention, only 58 patients did not have documentation of current CRC
screening.
Conclusion
CRC is the third most prevalent cancer and second deadliest cancer in the U.S., with
higher incidences in Kentucky than the majority of other states (CDC, 2017). Because most
colorectal malignancies are slow-growing, CRC screening is vital in decreasing morbidity and
mortality. Although CRC prevention tests—such as colonoscopy or flexible sigmoidoscopy—
are the preferred screening modality, Cologuard® is a safe, non-invasive, and highly sensitive
option for patients preferring stool-based screening tests (ACS, 2017a).
Quality improvement groups can be instrumental in identifying a problem in practice and
working with various disciplines to improve upon that problem. In this study, a provider-based
intervention stemming from both group and individual contributions was chosen to address the
underutilization of Cologuard® in clinic. Presentation to clinic providers using the ACS’s
Clinician’s Reference and an overview of the clinic’s current procedures for ordering
Cologuard® was chosen as the provider-based intervention. Pre- and post- tests revealed a
statistically significant increase in provider knowledge and self-efficacy after the intervention.
While differences in provider attitudes and order rates of Cologuard were not statistically
significant, it is important to consider other implications for future practice, such as
modifications to the EHR or use of Cologuard® portal, to increase those measures. This
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initiative may provide necessary suggestions and first-steps to facilitate organizational changes
that would lead to an increase in Cologuard® orders.
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Appendix A. Pre-test of Knowledge, Attitudes, and Self-Efficacy Related to Cologuard
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Appendix B. Post-test of Knowledge, Attitudes, and Self-Efficacy Related to Cologuard
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Table 1. Recommendations for Common CRC Screening Modalities
Screening Modality

Screening Interval
(Negative result)

CRC Prevention Test


Colonoscopy

Every 10 years



Flexible sigmoidoscopy

Every 5 years



CT colonography

Every 5 years

CRC Detection Test (Non-Invasive)


High-sensitivity FIT test (several brands)

Yearly



High-sensitivity guaiac-based fecal occult blood test
(Hemoccult Sensa)

Yearly



FIT-DNA test (Cologuard®)

Every 3 years

(Rex et al., 2017)
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Table 2. Summary of Variables
Variable

Scoring Measure

Time-point of
Measure

Knowledge of
Cologuard®
Attitudes about
Cologuard®
Provider selfefficacy

1-5 based on #
correct

Pre and Post

Likert scale

Pre and Post

Likert scale

Pre and Post

Cologuard® orders Yes vs. No

Pre and Post

Variable
Gender

Scoring measure
Male vs Female
Attending Physician
Resident Physician
Type of Provider
APP (Nurse Practitioner or
Physician’s Assistant)
Experience of Provider <5 years vs >5 years
Employment status
Full vs Part
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Level of
Measure
Interval

Data Source

Interval

Survey

Interval

Survey

Nominal

Electronic
Health Record

Timeline
Baseline

Survey

Level of Measure
Nominal
Nominal

Baseline
Baseline
Baseline

Nominal
Nominal
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Table 3. Summary of Provider Demographics

Providers in attendance
Surveys completed

n
18
14

Category

n

n(%)

6
6
2

42.9%
42.9%
14.2%

5
7
2
0

35.7%
50.0%
14.3%
0.0%

8
1
5

57.1%
7.1%
35.7%

9
0
5

64.3%
0.0%
35.7%

Gender:
Male
Female
Did not specify
Type of Provider:
Attending
Resident
APP
Did not specify
Years of
Experience:
<5 years
>5 years
Did not specify
Employment Status:
Full-time
Part-time
Did not specify

n(%)
100%
77.8%
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Table 4. Statistical Analyses of Provider Knowledge, Attitudes, and Self-Efficacy
Potential range
Knowledge
Attitudes
Self-efficacy

0-5
5-25
5-25

Pre-education
Mean (SD)
3.36 (1.15)
19.41 (3.11)
19.07 (4.67)

* denotes statistically significant data based on p-value <0.05
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Post-education
Mean (SD)
4.71 (0.61)
20.64 (1.74)
23.29 (1.98)

P-value
<0.001 *
0.142
0.002 *
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Table 5. Statistical Analyses of Cologuard® Orders for Patients Not Up-To-Date with CRC
Screening

Pre-Intervention
Post-Intervention
Column Totals

Cologuard®
ordered: YES

Cologuard®
ordered: NO

Row Totals

1
(1.37) [1.10]
2
(1.63) [0.09]
3

48
(47.63) [0.00]
56
(56.37) [0.00]
104

49

𝑥 2 = 0.193
P-value = 0.660
The result is not significant at p < 0.05.
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107 (Grand Total)
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Figure 2. Percentage of Knowledge Questions Answered Correctly

86

2. Cologuard differs from other Fecal
Immunochemical Tests (FIT) in that:

86

Knoledge Questions

1. Cologuard would not be an appropriate CRC
screening method for a patient with the following:

93

100

3. Based on current USPSTF recommendations,
how often should Cologuard be repeated?

93
64

4. Correct Cologuard use requires a patient to
collect how many stool samples?

100
57

5. Medications and/or dietary choices may alter
Cologuard results.

86
43
0

Post-education

20

40

60

Percent Correct

Pre-education

3
39

80

100
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Figure 3. Measurement of Provider Attitudes

6. Cologuard is an effective CRC screening
test.

4.64
4.21

Attitudes Questions

7. I am likely to discuss Cologuard with
patients for whom screening is indicated.

4.86
4.5

8. I am likely to order Cologuard for patients
who prefer a stool-based test.

4.93
4.57

9. Documentation of Cologuard within the
EHR is clear and consistent.

2.57
2.43

10. Barriers exist that prevent me from
discussing and/or ordering Cologuard in the
primary care setting.

3.64
3.43
1

2

Post-education mean
Pre-education mean

Potential Range

3
40

3

4

5

EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®

Figure 4. Measurement of Provider Self-Efficacy

Self-Efficacy Questions

11. I am confident in my understanding of
Cologuard as an emerging CRC screening test.

4.57
4

12. I am comfortable discussing Cologuard as
a screening option with my patients.

4.64
4.21

13. I am confident in my understanding of the
clinic's procedure for ordering Cologuard.

4.71
3.5

14. I am confident in my understanding of the
clinic's procedure for obtaining Cologuard
results.

4.71
3.5

15. It is easy to access resources and/or
materials for Cologuard.

3.64
3.86
1

2

Post-education mean
Pre-education mean

Potential Range

3
41

3

4

5

EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®
Figure 5. Comparison of Cologuard® Order Rates Pre- and Post- Intervention
Pre-Intervention

Post-Intervention
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